Biodesix to Participate in Three Investor Conferences in November
Biodesix (Nasdaq: BDSX), a diagnostic solutions company specializing in lung disease, has announced its participation in three upcoming investor conferences in New York this November. CEO Scott Hutton and CFO Robin Cowie will attend the Craig-Hallum Alpha Select Conference on November 19, the Wolfe Research Healthcare Conference on November 20, and the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 21.
The company will deliver a presentation at the Canaccord event at 1:00 PM ET, which will be available via webcast on the Biodesix website's Investors section under 'News & Events'.
Biodesix (Nasdaq: BDSX), un'azienda di soluzioni diagnostiche specializzata nelle malattie polmonari, ha annunciato la sua partecipazione a tre prossime conferenze per investitori a New York questo novembre. Il CEO Scott Hutton e Il CFO Robin Cowie parteciperanno alla Craig-Hallum Alpha Select Conference il 19 novembre, alla Wolfe Research Healthcare Conference il 20 novembre e al Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum il 21 novembre.
L'azienda presenterà una sua esposizione all'evento Canaccord alle 13:00 ET, che sarà disponibile in streaming sul sito web di Biodesix nella sezione Investitori sotto 'News & Events'.
Biodesix (Nasdaq: BDSX), una empresa de soluciones diagnósticas especializada en enfermedades pulmonares, ha anunciado su participación en tres próximas conferencias para inversores en Nueva York este noviembre. El CEO Scott Hutton y El CFO Robin Cowie asistirán a la Craig-Hallum Alpha Select Conference el 19 de noviembre, a la Wolfe Research Healthcare Conference el 20 de noviembre y al Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum el 21 de noviembre.
La empresa realizará una presentación en el evento de Canaccord a la 1:00 PM ET, que estará disponible a través de una transmisión en vivo en la sección de Inversores del sitio web de Biodesix bajo 'News & Events'.
Biodesix (Nasdaq: BDSX)는 폐 질환 전문 진단 솔루션 회사로, 이번 11월 뉴욕에서 개최되는 세 곳의 투자자 컨퍼런스에 참여한다고 발표했습니다. CEO 스콧 해튼과 CFO 로빈 코위는 11월 19일에 열리는 크레이그-할럼 알파 셀렉트 컨퍼런스, 11월 20일의 울프 리서치 헬스케어 컨퍼런스, 그리고 11월 21일의 카나코드 제뉴이티 메드텍, 진단 및 디지털 건강 및 서비스 포럼에 참석할 예정입니다.
회사는 카나코드 행사에서 오후 1시에 발표를 진행할 예정이며, Biodesix 웹사이트의 투자자 섹션에서 '뉴스 및 이벤트' 아래에서 웹캐스트를 통해 이용 가능합니다.
Biodesix (Nasdaq: BDSX), une entreprise de solutions diagnostics spécialisée dans les maladies pulmonaires, a annoncé sa participation à trois prochaines conférences pour investisseurs à New York ce novembre. Le PDG Scott Hutton et le CFO Robin Cowie assisteront à la Craig-Hallum Alpha Select Conference le 19 novembre, à la Wolfe Research Healthcare Conference le 20 novembre, et au Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum le 21 novembre.
La société fera une présentation lors de l'événement Canaccord à 13h00 ET, qui sera disponible par webcast dans la section Investisseurs du site web de Biodesix sous 'News & Events'.
Biodesix (Nasdaq: BDSX), ein Unternehmen für diagnostische Lösungen, das sich auf Lungenerkrankungen spezialisiert hat, hat seine Teilnahme an drei kommenden Investorenkonferenzen in New York im November angekündigt. CEO Scott Hutton und CFO Robin Cowie werden an der Craig-Hallum Alpha Select Conference am 19. November, der Wolfe Research Healthcare Conference am 20. November und dem Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum am 21. November teilnehmen.
Das Unternehmen wird um 13:00 Uhr ET eine Präsentation auf der Canaccord-Veranstaltung halten, die über einen Webcast im Investorenbereich der Biodesix-Website unter 'News & Events' verfügbar sein wird.
- None.
- None.
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:
Craig-Hallum 15th Annual Alpha Select Conference
1x1 Meetings
Date: Tuesday, November 19, 2024
Location: New York, NY
Wolfe Research Healthcare Conference 2024
1x1 Meetings
Date: Wednesday, November 20, 2024
Location: New York, NY
Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum
Presentation and 1x1 Meetings
Presentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ET
Location: New York, NY
The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.
About Biodesix
Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit biodesix.com.
Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.
Contacts:
Media:
Natalie St. Denis
Natalie.StDenis@biodesix.com
1-720-925-9285
Investors:
Chris Brinzey
chris.brinzey@westwicke.com
1-339-970-2843
FAQ
When is Biodesix (BDSX) presenting at the Canaccord Genuity Conference in November 2024?
Which investor conferences is Biodesix (BDSX) attending in November 2024?